CC clears Optimax’s acquisition of Ultralase
The Competition Commission today published its final report clearing Optimax’s completed acquisition of refractive eye surgery provider, Ultralase, on “failing firm” grounds. Such clearances remain relatively rare, but in this case the CC was satisfied that, absent Optimax’s acquisition, Ultralase would have exited the market. It went on to compare the likely distribution of Ultralase’s sales in the event of an exit with the actual distribution post-merger, and concluded the merger was not a less competitive outcome.
Optimax was represented by Alison Berridge and Michael Armitage.